Figure S1 - Protocol-specified cardiac toxicity algorithm

LVEF assessment

Type B cardiac event or LVEF < 50%

STOP NPLD

LVEF ≥ 50%

CONTINUE with all study medication

LVEF ≤ 44%

LVEF = 45-49%

WITHHOLD trastuzumab and pertuzumab and repeat LVEF in 3 weeks

LVEF = 45-49% and decrease ≥10p from baseline or LVEF >49%

WITHHOLD trastuzumab and pertuzumab and repeat LVEF in 3 weeks

LVEF ≤44% or LVEF = 44%-49% and decrease ≥10p from baseline

STOP trastuzumab y pertuzumab

LVEF = 45-49% and decrease <10p from baseline or LVEF >49%

RESTART trastuzumab and pertuzumab

LVEF ≤44% or LVEF = 44%-49% and decrease ≥10p from baseline

STOP trastuzumab y pertuzumab

LVEF = 45-49% and decrease <10p from baseline or LVEF >49%

RESTART trastuzumab and pertuzumab